Nephrectomies at Lymph Node Dissection Are Declining

This article originally appeared here.
Share this content:
Rate of Nephrectomy at Lymph Node Dissection Is Declining
Rate of Nephrectomy at Lymph Node Dissection Is Declining

(HealthDay News) -- Over the last 30 years, the incidence of nephrectomy at post-chemotherapy (PC) retroperitoneal lymph node dissection (RPLND) has steadily declined, according to research published in the March issue of The Journal of Urology.

K. Clint Cary, M.D., of the University of California in San Francisco, and colleagues retrospectively reviewed a database to identify a total of 1,807 patients diagnosed with testis cancer (TC) between 1980 and 2007 to determine what clinical and pathological features were associated with nephrectomy at PC RPLND.

The overall incidence of nephrectomy at PC RPLND was 14.8%, but this rate has steadily declined over the past 30 years. The incidence was higher in patients with larger volume tumors, those who received salvage chemotherapy, those with a left primary testicular tumor, and patients with increased markers at post-chemotherapy surgery. Patients with a retroperitoneal mass of 10 cm or larger were 9.3-fold more likely to undergo a PC RPLND.

"The overall incidence of nephrectomy at PC RPLND is 14.8%. This decreased in the last 30 years, most likely due to a combination of factors, including greater understanding of TC pathology and increased surveillance," the authors write. "Regardless of RP histology, a mass less than 2 cm rarely necessitates nephrectomy. Larger RP masses (greater than 5 cm) and left primary tumors are strong predictors of an increased incidence of nephrectomy. Surgeons who treat this patient population should use sound preoperative and intraoperative judgment when considering nephrectomy at PC RPLND."

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs